Skip to content
AFCG

Advanced Flower Capital Inc.

Advanced Flower Capital Inc. Q3 FY2025 earnings call

November 12, 2025 · fiscal period ended 2025-09

EPS · actual vs est

$0.16 / $0.19Miss -15.8%

Revenue · actual vs est

$-841,830 / $5.4MMiss -115.7%
Ask about this call

Summary

Generated 2025-11-12

Management highlights

• Shareholder vote: In November 2025, shareholders approved proposals for converting to a BDC, including a new investment advisory agreement and reduced asset coverage requirements. Conversion to BDC expected in 2026 while continuing as REIT until then. • Portfolio updates: Private Company J and a subsidiary of Public Company S paid off term loans; capital redeployed. Underperforming loans: Private Company A's receivership distributed $4,200,000 to Advanced Flower Capital Inc.; Private Company K's dispensaries in process of sale; settlement reached with Private Company P with $13,300,000 settlement (loan had carrying value $15,300,000). • Pipeline: Approximately $350,000,000 pipeline of non-cannabis lending opportunities, expanding investment mandate beyond cannabis. • Financial results: Net interest income $6.5M, distributable earnings $3.5M, GAAP net loss $12.5M, book value per share $7.49 as of 09/30/2025.

View in transcript ↓

Segment performance

For the quarter ended 09/30/2025, Advanced Flower Capital Inc. generated net interest income of $6,500,000 and distributable earnings of $3,500,000 or $0.16 per basic weighted share of common stock. It had a GAAP net loss of $12,500,000 or a loss of $0.57 per basic weighted average share. As of 09/30/2025, the CECL reserve was $51,300,000 (approximately 18.7% of loans at carrying value) and there was a total unrealized loss of $31,200,000 on loans held at fair value. Principal outstanding was $327,700,000 across 14 loans as of 11/03/2025, and book value per share was $7.49.

View in transcript ↓

Guidance

• Conversion to BDC is expected in 2026. • No Q4 2025 dividend anticipated due to the approximately $4,000,000 taxable loss from the Private Company P settlement. • Actively evaluating a $350,000,000 pipeline of non-cannabis lending opportunities for redeployment as BDC.

View in transcript ↓

Risks

• Uncertainty regarding timing of repayments and recovery of nonaccrual loans. • Dependence on progress in the cannabis industry for future investment opportunities in that space. • Market uncertainties and macro factors that could impact investment performance in new industries being evaluated.

View in transcript ↓

Q&A highlights

Q: Aaron Thomas Grey asked about the $350,000,000 non-cannabis pipeline being inclusive of the total pipeline and color on opportunities/yields.

A: Daniel Neville responded that the $350M includes the cannabis pipeline, yields on non-cannabis are in low double-digit range, more selective on deals now.

Q: Pablo Zuanic asked about timing of redeploying cash, diversification, skill set in new industries.

A: Daniel Neville stated no specific guidance on redeployment timing, casting wide net in new industries, team has experience in direct lending across industries.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$0.16$0.19-15.8%$0.35
Revenue$-841,830$5.4M-115.7%$8.7M

Transcript

November 12, 2025

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.